SCHEMBL5022652

SCHEMBL5022652

CCOc1ccc(C=O)c2c1oc1ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
LMNA P02545 4/20 0.44
ALDH1A1 P00352 6/20 0.44
MAPT P10636 4/20 0.44
HPGD P15428 2/20 0.44
ALOX12 P18054 1/20 0.44
NTSR1 P30989 1/20 0.44
CCR6 P51684 1/20 0.44
MCL1 Q07820 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CYP2A6 P11509 1/20 0.43
TP53 P04637 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
GAA P10253 2/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1647979 0.85 MAOA (0.52) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL5022822 0.84 MAPT (0.48) LMNAALDH1A1MAPTHPGDNPSR1
SCHEMBL5016548 0.82 CYP19A1 (0.51) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL2556489 0.82 CYP19A1 (0.40) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL5016468 0.81 CYP19A1 (0.47) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL3724543 0.79 MAOA (0.57) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL8169795 0.78 PDE4B (0.43) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL5026641 0.77 CYP19A1 (0.47) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL8299604 0.75 CYP19A1 (0.45) CYP19A1CYP11B1CYP11B2LMNAALDH1A1
SCHEMBL5018006 0.75 CYP19A1 (0.49) CYP19A1CYP11B1CYP11B2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2008-06-19 US disclosed
EP-1554262-B1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LTD (IN) 2007-12-05 EP disclosed
US-7238725-B2 Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS LTD. (IN) 2007-07-03 US disclosed
US-20060178418-A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them GLENMARK PHARMACEUTICALS LTD. (IN) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LTC4S, TSLP, GPR119 CYP19A1 248/4885CYP11B1 96/4885CYP11B2 105/4885
US-20060178418-A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them LTC4S, TSLP, GPR119 CYP19A1 248/4885CYP11B1 96/4885CYP11B2 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.